efgartigimod alfa-fcab (Vyvgart)

Indications

• treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
• treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in combination with hyaluronidase-qvfc (Vyvgart Hytrulo)

Dosage

• recommended dosage is 10 mg/kg administered as an intravenous infusion over one hour once weekly for 4 weeks
• in patients weighing >= 120 kg, the recommended dose is 1200 mg per infusion.
• CDIP: weekly 30-to-90 second subcutaneous injection

Injection: 400 mg in 20 mL (20 mg/mL) single-dose vial

Adverse effects

• hypersensitivity reactions: angioedema, dyspnea, & rash
• common (>= 10%): respiratory tract infections, headache, urinary tract infection

• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• human IgG1 antibody fragment that binds to & inhibits the neonatal Fc receptor resulting in the reduction of circulating IgG

More general terms

• pharmaceutical monoclonal antibody
• neurologic agent

Component of

• efgartigimod/hylenex